Guangzhou and London – May 22, 2025 – Bio-Thera Solutions,Ltd (688177:SH), a commercial-stage biopharmaceutical company developing apipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC,along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announcedtha...
DetailsOn September 5 2016,Bio-thera reached a strategic cooperation agreement with world class CRO, Quintiles. Under agreement with Bio-Thera, Quintileswith provide all-around international clinicalstudy and filingcooperative supportfor new drugs developed by Bio-thera. The signing ceremony was held at th...
Great news! On May 18, Bio-Thera's recombinant humanized anti-VEGF monoclonal antibody injection (BAT1706 ) was approved for clinical trials by the China Food and Drug Administration (CFDA), marking our second approval for biosimilar clinical trials this year. BAT1706 is a bevacizumab biosimilar ind...
On March 15, there was some big news for one of Bio-Thera's major pipeline products. The phase I clinical trial for BAT1706 (a bevacizumab biosimilar), which is currently carrying out its global development plan, has enrolled its first two healthy subjects in New Zealand. This is the first clinical ...
